Innate Pharma S.A. (NASDAQ:IPHA) Sees Large Growth in Short Interest

Innate Pharma S.A. (NASDAQ:IPHA) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 909,800 shares, a growth of 1,344.1% from the November 30th total of 63,000 shares. Based on an average trading volume of 461,600 shares, the days-to-cover ratio is presently 2.0 days.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on IPHA shares. Evercore ISI raised Innate Pharma to a “strong-buy” rating in a research report on Monday, September 16th. HC Wainwright restated a “buy” rating and issued a $11.50 price objective on shares of Innate Pharma in a report on Monday, December 9th.

Innate Pharma Stock Up 2.4 %

Shares of Innate Pharma stock traded up $0.05 during midday trading on Thursday, reaching $2.11. 41,706 shares of the company’s stock traded hands, compared to its average volume of 127,127. Innate Pharma has a 52 week low of $1.29 and a 52 week high of $3.51. The company’s 50 day simple moving average is $1.80 and its 200 day simple moving average is $2.05.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.